A5050860983- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Neonatal Health and Biochemistry
- Folate and B Vitamins Research
- Metabolism and Genetic Disorders
- Multiple and Secondary Primary Cancers
- Genetic factors in colorectal cancer
- Immunodeficiency and Autoimmune Disorders
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Head and Neck Cancer Studies
- Oral and gingival health research
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
Althaia
2017-2025
Universitat de Vic - Universitat Central de Catalunya
2021-2024
Hospital Sant Joan de Déu Barcelona
2020-2023
Institut Català d'Oncologia
2009-2022
Hospital Universitari Germans Trias i Pujol
2010-2020
Josep Carreras Leukaemia Research Institute
2012-2019
Universitat Autònoma de Barcelona
2009-2017
Weatherford College
2015
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there limited real-world evidence. Here we evaluated the efficacy safety of KRd in RRMM treated following standard clinical practice hospitals Catalan region. This was retrospective, observational study. The objective response rate (ORR) according to IMWG criteria primary endpoint. Secondary endpoints included progression-free...
Summary Richter syndrome (RS) is an uncommon evolution of chronic lymphocytic leukaemia (CLL) with a dismal prognosis. Clinical‐biological features predicting outcome and best therapeutic approach for these patients remain to be established. In this study, 128 RS, including 112 diffuse large B‐cell lymphoma (DLBCL)‐type 15 Hodgkin (HL)‐type one plasmablastic lymphoma, were identified in 11 centres the Spanish CLL Study Group (GELLC). The median overall survival (OS) was 5·9 months DLBCL‐type...
BACKGROUND The karyotype is a predictor of outcomes in adults with acute lymphoblastic leukemia (ALL). unfavorable prognostic significance complex (CK) has been reported, whereas the relevance monosomal (MK) not consistently evaluated. We aimed to assess value CK and MK ALL treated risk‐adapted protocols Spanish PETHEMA Group. METHODS karyotypes 881 adult patients according Group between 1993 2012 were centrally reviewed. assessed Moorman's criteria, Breem's respectively. Specific analyses...
Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, small percentage of patients responds poorly treatment and seems have worse outcome. This study attempted identify the predictive factors outcome refractoriness first-line ICT. All diagnosed with stage II IV follicular between 2002 2014 treated ICT in 4 Spanish institutions were analyzed. Those no or progression relapse within 6 months assessment considered refractory. Three hundred forty-three...
About 25-35% of adult patients with acute lymphoblastic leukemia show the Philadelphia (Ph) chromosome. Few series have evaluated prognosis additional cytogenetic alterations (ACA) to Ph We analyzed frequency, type and prognostic significance ofACA in adults (18-60 years) treated ALL-Ph-08 trial. Fifty-two out 74 (70%) showed ACA 19 (26%) presented monosomies associated t(9;22) (monosomal karyotype, MK). Similar complete response (CR) rate, CR duration, overall survival event-free (EFS) were...
This phase I/II trial evaluated the combination of kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) patients. Forty-seven RRMM patients a median three prior lines (2-8) 94% to lenalidomide were included: 14 I 33 II. The recommended dose was 1·25 mg/m2 on days 1, 2, 15, 16, 4 mg 1-21 40 weekly. defined threshold for success achieved, 18 out 31 obtaining at least minor response (MR) In global population, 51%...
Immunoparesis (IP) in multiple myeloma (MM) patients can be measured by classic assessment of immunoglobulin (Ig) levels or analysis the uninvolved heavy/light chain pair same (uHLC) Hevylite® assay. In this study we evaluate prognostic value recovery from IP total Ig and uHLC newly diagnosed MM transplant-eligible (NDMM-TE) with intensive treatment its association Minimal Residual Disease (MRD). Patients were enrolled treated PETHEMA/GEM2012MENOS65 trial continued PETHEMA/GEM2014MAIN trial....
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. In myeloma (MM), measurable residual disease (MRD) is assessed bone marrow (BM). However, less invasive evaluation...
The karyotype is an important predictor of outcome in acute lymphoblastic leukemia (ALL). Rearrangements the 11q23 region involving KMT2A gene confer unfavorable prognosis. Forty-six adult ALL patients from PETHEMA Group treated with risk-adapted protocols, t(v;11q23) were selected for this study. Complete response (CR) was attained 38 patients; 25 remained CR after consolidation. Twelve (48%) received allogeneic hematopoietic stem cell transplantation (HSCT) and 13 delayed intensification...
Abstract Previous studies showed antitumor activity for plitidepsin plus dexamethasone (DXM) in relapsed/refractory multiple myeloma (r/r MM), and vitro synergism with bortezomib (BTZ) or DXM against MM cells. This phase I trial evaluated (3‐h intravenous infusion Day 1 15), BTZ (subcutaneous bolus 1, 4, 8, 11), (orally 15, 22), every 4 weeks 36 r/r patients. Twenty‐two patients were treated using a standard dose escalation design (10 at the recommended [RD] cohort), 14 additional to expand...
It is unclear whether higher CD34 + cell doses infused for ASCT have any influence on survival or relapse in patients with lymphoma. We analyzed the correlation of dose relapse, survival, and hematopoietic recovery 146 consecutive undergoing Higher (>5 × 106/kg) were significantly correlated earlier recovery, fewer infectious episodes, lower transfusion needs. No differences observed lymphoma outcomes (4-year incidence 38% [95%CI: 29%-48%] group versus 51% 30%-69%] group, 10-year OS...